Mentice

Mentice Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Mentice (MNTC.ST) as of Nov 19, 2026 is 0.65. In the previous year, Net Debt to Free Cash Flow Ratio was -30.01 — a change of -102.17% (higher).

Net Debt/FCF

0.65

YoY

-102.17%

Last updated:

Net Debt to Free Cash Flow Ratio of Mentice is 2025 0.65 . Net Debt to Free Cash Flow Ratio of Mentice was 2024 -30.01 . It decreases by -102.17% higher compared to the previous year.

The Mentice Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
-15.69 SEK
Jan 1, 2019
0.79 SEK
Jan 1, 2020
-7.17 SEK
Jan 1, 2021
-0.06 SEK
Jan 1, 2022
-16.51 SEK
Jan 1, 2023
-1.68 SEK
Jan 1, 2024
-30.01 SEK
Jan 1, 2025
0.65 SEK
The Mentice Net Debt/FCF history
YEARNet Debt/FCFYoY
0.65-102.17%
-30.01+1,688.13%
-1.68-89.83%
-16.51+25,427.95%
-0.06-99.10%
-7.17-1,007.21%
0.79-105.03%
-15.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mentice Stock analysis

What does Mentice do? Mentice AB provides software and hardware simulation solutions for endovascular therapies, targeting healthcare professionals and the medical device industry. The company's solutions are scientifically validated and designed to help users acquire, retain, and enhance procedural skills in neurovascular, cardiovascular, and peripheral interventions. Mentice AB generates revenue through the sale of its simulation products and related services, with key buyers including healthcare providers and medical device manufacturers. The company operates globally, serving clients across multiple healthcare segments that require advanced training tools for minimally invasive procedures. Mentice AB's business model focuses on delivering scientifically validated simulation tools that address skill development needs in complex medical procedures. The firm's product offerings cater to both healthcare institutions seeking to train staff and medical device companies requiring validation tools for their products. By specializing in endovascular therapy simulations, Mentice AB serves a niche market with high demand for precise procedural training solutions. The company's global presence allows it to reach clients in various regions seeking advanced medical simulation technology. The company's revenue streams come from the sale of simulation software and hardware systems alongside ongoing service contracts. Healthcare providers purchase these solutions to improve staff competency in endovascular procedures, while medical device manufacturers use them to validate device performance in simulated environments. Mentice AB's solutions are specifically developed for the medical device industry and healthcare providers, creating a dual revenue stream from both sectors. The firm's focus on scientifically validated tools ensures strong market positioning within specialized medical training segments. Mentice is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mentice stock

Net Debt to Free Cash Flow Ratio of Mentice is 0.65 in 2025.

Net Debt to Free Cash Flow Ratio of Mentice changed from -30.01 to 0.65, representing a -102.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Mentice since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Mentice with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Mentice

All Key Metrics — Mentice